Academic Journal
أعرض في EDS

Neoadjuvant chemotherapy plus radical cystectomy versus radical cystectomy alone in clinical T2 bladder cancer without hydronephrosis

التفاصيل البيبلوغرافية
العنوان: Neoadjuvant chemotherapy plus radical cystectomy versus radical cystectomy alone in clinical T2 bladder cancer without hydronephrosis
المؤلفون: Soria, Francesco, Black, Peter C., Fairey, Adrian S., Cookson, Michael S., Yu, Evan Y., Kassouf, Wassim, Dall’Era, Marc A., Sridhar, Srikala S., McGrath, John S., Wright, Jonathan L., Thorpe, Andrew C., Morgan, Todd M., Daneshmand, Siamak, Holzbeierlein, Jeff M., Bivalacqua, Trinity J., North, Scott, Barocas, Daniel A., Lotan, Yair, Grivas, Petros, Stephenson, Andrew J., Shah, Jay B., Rhijn, Bas W., Spiess, Philippe E., Shariat, Shahrokh F., Gontero, Paolo
بيانات النشر: Wiley Periodicals, Inc.
سنة النشر: 2021
المجموعة: University of Michigan: Deep Blue
مصطلحات موضوعية: #utuc, neoadjuvant chemotherapy, bladder cancer, clinical T2, hydronephrosis, downstaging, #BladderCancer, #blcsm, #uroonc, Internal Medicine and Specialties, Health Sciences
الوصف: Peer Reviewed ; http://deepblue.lib.umich.edu/bitstream/2027.42/168363/1/bju15289.pdf ; http://deepblue.lib.umich.edu/bitstream/2027.42/168363/2/bju15289_am.pdf
نوع الوثيقة: article in journal/newspaper
وصف الملف: application/pdf
اللغة: unknown
تدمد: 1464-4096
1464-410X
Relation: Soria, Francesco; Black, Peter C.; Fairey, Adrian S.; Cookson, Michael S.; Yu, Evan Y.; Kassouf, Wassim; Dall’Era, Marc A.; Sridhar, Srikala S.; McGrath, John S.; Wright, Jonathan L.; Thorpe, Andrew C.; Morgan, Todd M.; Daneshmand, Siamak; Holzbeierlein, Jeff M.; Bivalacqua, Trinity J.; North, Scott; Barocas, Daniel A.; Lotan, Yair; Grivas, Petros; Stephenson, Andrew J.; Shah, Jay B.; Rhijn, Bas W.; Spiess, Philippe E.; Shariat, Shahrokh F.; Gontero, Paolo (2021). "Neoadjuvant chemotherapy plus radical cystectomy versus radical cystectomy alone in clinical T2 bladder cancer without hydronephrosis." BJU International (1): 79-87.; https://hdl.handle.net/2027.42/168363; BJU International; Liu W, Tian J, Zhang S et al. The utilization status of neoadjuvant chemotherapy in muscle‐invasive bladder cancer: a systematic review and meta‐analysis. Minerva Urol Nefrol 2020 [Online ahead of print]. DOI: https://doi.org/10.23736/S0393‐2249.19.03648‐8; Witjes JA, Bruins HM, Cathomas R et al. European Association of Urology guidelines on muscle‐invasive and metastatic bladder cancer: summary of the 2020 guidelines. Eur Urol 2020 [Online ahead of print]. DOI: https://doi.org/10.1016/j.eururo.2020.03.055; Zargar H, Zargar‐Shoshtari K, Lotan Y et al. Final pathological stage after neoadjuvant chemotherapy and radical cystectomy for bladder cancer‐does pT0 predict better survival than pTa/Tis/T1? J Urol 2016; 195: 886 – 93; Martini T, Gilfrich C, Mayr R et al. The use of neoadjuvant chemotherapy in patients with urothelial carcinoma of the bladder: current practice among clinicians. Clin Genitourin Cancer 2017; 15: 356 – 62; Black PC, Brown GA, Grossman HB, Dinney CP. Neoadjuvant chemotherapy for bladder cancer. World J Urol 2006; 24: 531 – 42; Rosenblatt R, Sherif A, Rintala E et al. Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle‐invasive urothelial bladder cancer. Eur Urol 2012; 61: 1229 – 38; Hermans TJ, Voskuilen CS, Deelen M et al. Superior efficacy of neoadjuvant chemotherapy and radical cystectomy in cT3‐4aN0M0 compared to cT2N0M0 bladder cancer. Int J Cancer 2019; 144: 1453 – 9; Advanced Bladder Cancer Overview Collaboration. Advanced Bladder Cancer Meta‐analysis Collaboration. Neo‐adjuvant chemotherapy for invasive bladder cancer. Cochrane Database Syst Rev 2004; 2: CD005246; Winquist E, Kirchner TS, Segal R, Chin J, Lukka H. Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a systematic review and meta‐analysis. J Urol 2004; 171: 561 – 9; Sherif A, Holmberg L, Rintala E et al. Neoadjuvant cisplatinum based combination chemotherapy in patients with invasive bladder cancer: a combined analysis of two Nordic studies. Eur Urol 2004; 45: 297 – 303; Green DA, Rink M, Hansen J et al. Accurate preoperative prediction of non‐organ‐confined bladder urothelial carcinoma at cystectomy. BJU Int 2013; 111: 404 – 11; Culp SH, Dickstein RJ, Grossman HB et al. Refining patient selection for neoadjuvant chemotherapy before radical cystectomy. J Urol 2014; 191: 40 – 7; Moschini M, Soria F, Klatte T et al. Validation of preoperative risk grouping of the selection of patients most likely to benefit from neoadjuvant chemotherapy before radical cystectomy. Clin Genitourin Cancer 2017; 15: e267 – 73; Griffiths G. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle‐invasive bladder cancer: long‐term results of the BA06 30894 trial. J Clin Oncol 2011; 29: 2171 – 7; Grossman HB, Natale RB, Tangen CM et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 2003; 349: 859 – 66; Yin M, Joshi M, Meijer RP et al. Neoadjuvant chemotherapy for muscle‐invasive bladder cancer: a systematic review and two‐step meta‐analysis. Oncologist 2016; 21: 708 – 15
DOI: 10.1111/bju.15289
الاتاحة: https://hdl.handle.net/2027.42/168363
https://doi.org/10.1111/bju.15289
Rights: IndexNoFollow
رقم الانضمام: edsbas.3E680483
قاعدة البيانات: BASE
الوصف
تدمد:14644096
1464410X
DOI:10.1111/bju.15289